First-Episode Psychosis
8
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
Trial to Increase FEP Attendance
Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode
Using mHealth to Optimize Pharmacotherapy Regimens
Clinical Interviews With Detainees With Early Psychosis
HIIT in Patients With a First-episode Psychosis
COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI